Scientists pinpoint ideal painkiller dose for diabetic foot operations
NCT ID NCT04981067
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to find the smallest effective dose of the numbing drug ropivacaine for blocking leg nerves during diabetic foot surgery. Researchers will test different concentrations in 45 adults to see which dose works best for 90% of patients. The goal is to provide effective pain relief while using the lowest possible amount of medicine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropivacaine
What this could lead to
If successful, this could help doctors use the right amount of numbing medicine for diabetic foot surgery, reducing pain and risks.
What could go wrong
This is a small, early-phase study with only 45 people. The results may not apply to everyone, and the best dose might still cause side effects or fail to numb properly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC FOOT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea